Cibc World Markets Corp Buys 5,075 Shares of Hologic, Inc. (NASDAQ:HOLX)

Cibc World Markets Corp lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 16.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,676 shares of the medical equipment provider's stock after purchasing an additional 5,075 shares during the quarter. Cibc World Markets Corp's holdings in Hologic were worth $2,644,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. General Partner Inc. bought a new position in Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment boosted its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HOLX. Citigroup lowered their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Stephens reaffirmed an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Evercore ISI dropped their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a report on Thursday, February 6th. Argus lowered Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Raymond James reiterated an "outperform" rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Stock Performance

HOLX stock traded down $1.09 during mid-day trading on Tuesday, hitting $60.80. 2,378,047 shares of the company were exchanged, compared to its average volume of 1,754,307. The business has a 50 day simple moving average of $65.89 and a 200-day simple moving average of $73.81. The stock has a market capitalization of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.